[1]赵新荣,杨炜,邱明磊,等.玻璃体内注射雷珠单抗联合玻璃体切割术治疗严重增生型糖尿病视网膜病变[J].眼科新进展,2015,35(11):1064-1066.[doi:10.13389/j.cnki.rao.2015.0291]
　ZHAO Xin-Rong,YANG Wei,QIU Ming-Lei,et al.Ranibizumab injection and vitrectomy for severe proliferative diabetic retinopathy[J].Recent Advances in Ophthalmology,2015,35(11):1064-1066.[doi:10.13389/j.cnki.rao.2015.0291]
点击复制

玻璃体内注射雷珠单抗联合玻璃体切割术治疗严重增生型糖尿病视网膜病变
分享到：

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
35卷
期数:
2015年11期
页码:
1064-1066
栏目:
应用研究
出版日期:
2015-11-05

文章信息/Info

Title:
Ranibizumab injection and vitrectomy for severe proliferative diabetic retinopathy
作者:
赵新荣; 杨炜; 邱明磊; 张奕霞; 蔡新雨; 罗远湘
832008　新疆维吾尔自治区石河子市，石河子大学医学院第一附属医院眼科
Author(s):
ZHAO Xin-Rong; YANG Wei ;  QIU Ming-Lei ; ZHANG Yi-Ya ; CAI Xin-Yu ;  LUO Yuan-Xiang
Department of Ophthalmology,the First Affiliated Hospital of Medical College of Shihezi University,Shihezi 832008 ,Xinjiang Uyghur Autonomous Region，China
关键词:
雷珠单抗; 增生型糖尿病视网膜病变; 玻璃体切割术
Keywords:
ranibizumab ;  proliferative diabetic retinopathy ;  vitrectomy
DOI:
10.13389/j.cnki.rao.2015.0291
文献标志码:
A
摘要:
目的　观察玻璃体内注射雷珠单抗联合玻璃体切割术治疗严重增生型糖尿病视网膜病变（ｐｒｏｌｉｆｅｒａｔｉｖｅｄｉａｂｅｔｉｃｒｅｔｉ-ｎｏｐａｔｈｙ，ＰＤＲ）的临床效果。方法　将临床确诊为严重ＰＤＲ的患者５２例７２眼纳入本研究。依据术前是否行玻璃体内注射雷珠单抗将患者分为治疗组和对照组：治疗组３０例４２眼、对照组２２例３０眼。治疗组术前３ｄ玻璃体内注射１０ｇ·Ｌ－１雷珠单抗０．０５ｍＬ（０．５ｍｇ），然后行玻璃体切割术，对照组直接行玻璃体切割术。术后随访３～１２（６．５±１．３）个月。对比分析两组患者视力、眼压、黄斑中心凹视网膜厚度和术后并发症的发生情况。结果　治疗组、对照组手术后视力分别为０．０９０±０．０６８、０．０６０±０．０２９，均较术前提高，２组治疗前、治疗后视力比较差异均有统计学意义（ｔ＝－５．００５、－３．２３７，均为Ｐ＜０．０５）。两组术后视力比较，差异有统计学意义（ｔ＝２．０３４，Ｐ＜０．０５）。治疗组、对照组术后黄斑中心凹视网膜厚度分别为（３１３．８±２７．３）μｍ、（３２５．６±１４．５）μｍ，差异有统计学意义（ｔ＝－１．５１，Ｐ＜０．０５）。术后２周、１个月、３个月，治疗组玻璃体积血发生率分别为１２％、２％、２％，对照组发生率分别为２７％、２０％、３％；两组术后各时间点发生率比较，术后２周及１个月之间差异均有统计学意义（χ２＝３．４２、３．２１，均为Ｐ＜０．０５），术后３个月差异无统计学意义（χ２＝１．０２，Ｐ＞０．０５）。结论　玻璃体切割术联合玻璃体内注射雷珠单抗治疗严重ＰＤＲ能提高患者视力，降低术后玻璃体积血发生率和黄斑中心凹视网膜厚度。
Abstract:
Objective To observe the clinical effects of vitrectomy assisted with intravitreal injection of ranibizumab for severe proliferative diabetic retinopathy( PDR) . Methods A total of 52 patients( 72 eyes) with severe PDR were enrolled.and divided into treatment group ( 30 patients ,42 eyes) and control group ( 22 patients , 30 eyes ) . The patients in treatment group received an intravitreal injection of 0. 05 mL rarubizumab solution( 10 g . L ’l ) firstly, and 3 0r 4 days later they received vitrectomy. The patients in control group only received vitrectomy. The follow-up time was 3 months t0 12 months with an average of ( 6. 5 + 1. 3 ) months. The visual acuity, intraocular pressure . central retinal thickness ( CRT) and incidence of postoperative complications were observed. Results The mean postoperative logMAR visual acuity in treatment group and control group were 0. 09 + 0. 068 and 0. 06 + 0. 029 .which were all higher than pre-operation , the difference was statistically significant ( t = - 5. 005 , - 3. 237 , all P < 0. 05 ). The mean post-operative logMAR visual acuity in treatment group was higher than that of control group , the difference was statistically significant ( t = 2. 034 .P < 0. 05 ) . The average postoperative CRT in treatment group and control group were ( 313. 8 + 27. 3) ym and ( 325 . 6 + 14. 5 ) ym , the difference was statistically sigruficant ( t = - 1. 51 .P < 0. 05 ) . The incidences of postoperative vitreous hemorrhage in treatment group and control group were 12% and 27% at 2 weeks after surgery,2% and 20% at I month after surgery,2% and 3% at 3 months after surgery , respectively , the differences was statistically significant for 2 weeks (X2 = 3. 42 ,P < 0. 05 ) and I month( t = 3. 21 ,P < 0. 05 ) .but there was no statistical difference for 3 months (X2 = 1. 02 ,P > 0. 05 ) . Conclusion Vitrectomy assisted with intravitreal injection of ranibizumab for severe PDR can effectively improve visual acuity , prevent postoperative vitreous hemorrhage and reduce CRT.

相似文献/References:

[1]衡欣 陈悦.增生型糖尿病视网膜病变患者血清中转化生长因子-β1和结缔组织生长因子水平的变化及意义[J].眼科新进展,2013,33(4):000.
[2]李姣 王兴荣 崔彦 刘正峰 王影 李洋.雷珠单抗选择性体外抑制睫状体恶性黑色素瘤[J].眼科新进展,2013,33(11):000.
[3]金昱,石安娜,刘淼. 玻璃体内注射雷珠单抗（Ranibizumab）治疗视网膜静脉阻塞继发黄斑水肿[J].眼科新进展,2014,34(9):855.[doi:10.13389/j.cnki.rao.2014.0236]
[4]张聪,刘东宁,徐丽. 玻璃体内注射Lucentis治疗中心性渗出性脉络膜视网膜病变的临床疗效[J].眼科新进展,2014,34(9):864.[doi:10.13389/j.cnki.rao.2014.0239]
[5]章晖,叶波,邱新文,等.雷珠单抗辅助23G玻璃体切割术治疗增生性糖尿病视网膜病变[J].眼科新进展,2014,34(10):975.[doi:10.13389/j.cnki.rao.2014.0270]
[6]王博,吴京,马明,等. 玻璃体内注射雷珠单抗与曲安奈德治疗糖尿病黄斑水肿的疗效对比分析[J].眼科新进展,2015,35(3):246.[doi:10.13389/j.cnki.rao.2015.0066]
　WANG Bo,WU Jing,MA Ming,et al. Clinictid effect comparison of intravitreal lucentis and triamcinolone acetonide for diabetic macular edema[J].Recent Advances in Ophthalmology,2015,35(11):246.[doi:10.13389/j.cnki.rao.2015.0066]
[7]刘斌,杨玉霞,刘杏,等. 雷珠单抗联合Ahmed青光眼阀植入术治疗新生血管性青光眼[J].眼科新进展,2015,35(3):263.[doi:10.13389/j.cnki.rao.2015.0070]
　LIU Bin,YANG Yu-Xia,LIU Xing,et al. Intravitreal lucentis injection combined with Ahmed valve implantation for neovascular glaucoma[J].Recent Advances in Ophthalmology,2015,35(11):263.[doi:10.13389/j.cnki.rao.2015.0070]
[8]刘志南,邓国华,江一. 光凝前雷珠单抗玻璃体内注射对CNV患者黄斑区视网膜及视功能的影响[J].眼科新进展,2015,35(4):365.[doi:10.13389/j.cnki.rao.2015.0098]
　LIU Zhi-Nan,DENG Guo-Hua,JIANG Yi. Effects of ranibizumab intravitreal injection before photocoagulation on macular retina and visual function in patients with CNV[J].Recent Advances in Ophthalmology,2015,35(11):365.[doi:10.13389/j.cnki.rao.2015.0098]
[9]万文萃,刘宇莹,尹向可,等. 玻璃体内注射抗血管内皮生长因子药物治疗急进性后部型早产儿视网膜病变[J].眼科新进展,2015,35(6):554.[doi:10.13389/j.cnki.rao.2015.0150]
　WAN Wen-Cui,LIU Yu-Ying,YIN Xiang-Ke,et al. Intravitreal injection of ranibizumab for aggressive posterior retinopathy of prematurity[J].Recent Advances in Ophthalmology,2015,35(11):554.[doi:10.13389/j.cnki.rao.2015.0150]
[10]李素华,高永峰. 比较单独黄斑局灶/格栅样光凝术和联合雷珠单抗治疗糖尿病性黄斑水肿的疗效[J].眼科新进展,2015,35(6):566.[doi:10.13389/j.cnki.rao.2015.0153]
　LI Su-Hua,GAO Yong-Feng. Efficacy of macular focal / grid photocoagulation combined with ranibizumab for diabetic macular edema[J].Recent Advances in Ophthalmology,2015,35(11):566.[doi:10.13389/j.cnki.rao.2015.0153]
[11]刘建伟,李聪伶,于海群.雷珠单抗玻璃体内注射对增生型糖尿病视网膜病变玻璃体切割术效果的影响[J].眼科新进展,2016,36(3):265.[doi:10.13389/j.cnki.rao.2016.0071]
　LIU Jian-Wei,LI Cong-Ling,YU Hai-Qun.Effects of intravitreal injection of ranibizumab on vitrectomy for proliferative diabetic retinopathy[J].Recent Advances in Ophthalmology,2016,36(11):265.[doi:10.13389/j.cnki.rao.2016.0071]
[12]刘爱琴,宋子宣,吴娟,等.雷珠单抗辅助玻璃体视网膜手术治疗增生型糖尿病视网膜病变[J].眼科新进展,2019,39(6):574.[doi:10.13389/j.cnki.rao.2019.0133]
　LIU Ai-Qin,SONG Zi-Xuan,WU Juan,et al.Ranibizumab assisted vitreoretinal surgery for the treatment of proliferative diabetic retinopathy[J].Recent Advances in Ophthalmology,2019,39(11):574.[doi:10.13389/j.cnki.rao.2019.0133]

备注/Memo

备注/Memo:
石河子大学医学院第一附属医院院级课题（编号：ＹＬ２０１０-Ｙ００３）
更新日期/Last Update: 2015-11-03